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Cytotoxicity of laronidase (Aldurazyme®), employed in 
enzyme replacement therapy (ERT) for mucopolysac-
charidosis type I (MPS I) and various siRNAs, tested pre-
viously in studies on substrate reduction therapy (SRT) 
for mucopolysaccharidoses, was tested. The enzyme did 
not cause any cytotoxic effects, and the siRNAs did not 
inhibit growth of most investigated cell lines. However, 
some cytotoxic effects of some tested siRNAs were ob-
served in one MPS IIIA cell line. The efficacy of a combi-
nation of enzyme replacement therapy and siRNA-based 
substrate deprivation therapy was tested on three MPS I 
cell lines. Surprisingly, different results were obtained for 
different cell lines. The decrease of glycosaminoglycan 
storage in cells treated simultaneously with both meth-
ods was: (i) less pronounced than obtained with either 
of those methods used alone in one cell line, (ii) similar 
to that observed for enzyme replacement therapy in an-
other cell line, and (iii) stronger than that obtained with 
either of the methods used alone in the third cell line. 
Therefore, it appears that the effects of various thera-
peutic methods may strongly depend on the features of 
the MPS cell line.
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INTRoduCTIoN
Mucopolysacharidoses (MPS) are a group of inherited 
metabolic diseases characterized by accumulation of gly-
cosaminoglycans (GAG) in lysosomes. These usually fa-
tal disorders are caused by mutation in genes coding for 
enzymes involved in degradation of GAGs (Neufeld & 
Muenzer, 2001). The activity deficiencies of appropriate 
lysosomal enzymes result in variable clinical phenotypes 
which include organomegaly, dysostis multiplex, decreased 
growth and respiratory insufficiency, and in some cases 
the central nervous system (CNS) is also affected (Neu-
feld & Muenzer, 2001). Mucopolysaccharidoses are di-
vided into seven distinct types, and into 11 subtypes 
depending on the deficient enzyme or clinical manifesta-
tion.
Since 1980 heamatopoietic stem cell transplantation 
(HSCT) has been used as a therapeutic approach in pa-
tients with severe MPSI (Peters et al., 1996; de Ru et al., 
2011). Beneficial effects may only be achieved in chil-
dren who have minimal or no symptoms from the CNS 
and this procedure is associated with a high incidence of 
graft failure, morbidity and mortality (Peters & Steward, 
2003). Enzyme replacement therapy (ERT) is another 
approved treatment of MPS. ERT is currently available 
for MPS I, MPS II and MPS VI (Beck, 2010). Introduc-
tion of human recombinant laronidase (Aldurazyme® 
Genzyme-Sanofi, Cambridge, MA, USA) in 2001 as the 
first ERT for mucopolysaccharidoses offered hope for 
patients and their families (Beck, 2010). Significant im-
provement in respiratory functions, physical capacity and 
reduction of organomegaly has been achieved (Kakkis 
et al., 2001; Wraith et al., 2004). However, neurological 
symptoms cannot be successfully treated due to the in-
sufficient delivery of the enzyme through the blood-brain 
barrier (BBB) (Beck, 2010). Other therapeutic approach-
es such as small synthetic chaperones, gene therapy, stop 
codon read-through strategy, and substrate deprivation 
therapy (SDT) are under detailed investigation (Jakób-
kiewicz-Banecka et al., 2007). One of them, SDT based 
on inhibition of GAG synthesis by genistein, is used in 
MPS III (Sanfilippo disease) (Piotrowska et al., 2006). 
Genistein (5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-ben-
zopyran-4-one, also known as 4’, 5, 7-trihydroxyisofla-
vone), an isoflavone able to cross the BBB is reported 
not only to reduce lysosomal storage, but also shows sig-
nificant improvement in cognitive function and general 
behavior (Piotrowska et al., 2008).
Recent studies on specific inhibition of GAG synthe-
sis by siRNA (small interfering RNA) have highlighted 
possible therapeutic applications for MPSs (Kaidonis 
et al., 2009; Dziedzic et al., 2010). Selective silencing of 
expression of a particular gene by specific degradation 
of corresponding mRNA became a standard laboratory 
procedure shortly after initial reports (Rana, 2007). RNA 
interference, first characterized in the nematode Cea-
norhabiditis elegans (Fire et al., 1998), has a potential for 
treating wide range of diseases. Preclinical trials are be-
ing performed for treatment of amyotrophic lateral scle-
rosis, age-related macular degeneration, hepatitis B and 
C, HIV, hepatic cancer and solid tumor cancers (Kim 
& Rossi, 2007; Snead & Rossi, 2012). However that ap-
proach has disadvantages like immune response, oversat-
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uration of endogenous pathways and off-targeting (Kim 
& Rossi, 2007).
The synthesis of glycosaminoglycans is initiated by for-
mation of GAG-protein linked tetrasaccharide, GlcAβ1-
3Galβ1-3Galβ1-4Xylβ1-O-Ser, to the core protein. Two 
variants of O-xylosyltransferases (XYLT1 and XYLT2) 
are responsible for the initiation step (Uyama et al., 2007). 
In the next phase two galactose (Gal) residues are at-
tached in reactions catalyzed by β1,4-galactosyltransferase 
7 (GALTI) and β1,3-galactosyltransferase 6 (GALTII). 
β1,3-glucuronosyltransferase (GLCATI) completes the 
biosynthesis by transferring a glucuronic acid (GlcA) res-
idue to the linkage trisaccharide (Prydz & Dalen, 2000). 
After the synthesis of the GAG sugar backbone, the 
first N-acetylgalactosamine (GalNAc) residue is trans-
ferred to the GlcA residue in the linkage region tetra-
saccharide by β1,4-N-acetylgalactosaminyltransferase I 
or II (GALNACTI or GALNACTII) activity, which is 
the beginning of the chain elongation process. Numer-
ous modifications including sulfation, epimerization, and 
desulfation lead to production of mature and functional 
GAG chains (Uyama et al., 2007).
The aims of this study were: first, to determine any 
possible cytotoxic effects caused by siRNA and ERT; 
second, to assess the effectiveness of siRNA-mediated 
silencing of genes coding for enzymes involved in the 
initial steps of GAG synthesis in comparison with the 
enzyme replacement therapy for MPS treatment; third, 
to combine both approaches for possible better efficien-
cy of treatment.
MATERIAlS ANd METHodS
Patients’ characteristics. Skin fibroblast lines were 
obtained from forearm skin biopsies from mucopolysac-
charidosis (MPS) type I, IIIA and IIIB patients and pro-
vided by The Children’s Memorial Health Institute (War-
saw, Poland). As a control healthy human dermal fibro-
blast (HDF) line was purchased from Cascade Biologics 
(Life Technologies, Carlsbad, CA, USA). Characteristics 
of MPS patients genotype are presented in Table 1.
Cell lines and culture conditions. Fibroblasts were 
cultured in 75cm2 culture flasks in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fe-
tal bovine serum (FBS) and 1x Antibiotic Antimycotic 
Solution (Sigma, St Louis, MO, USA) at 37°C in a hu-
midified atmosphere of 5% CO2. Once the cells reached 
90% confluency they were passaged into a 24-well plate 
and the experiment was performed. For the enzyme 
study cells were treated with laronidase (Aldurazyme®, 
Genzyme-Sanofi, Cambridge, MA, USA), a recombinant 
human α-L-iduronidase (IDUA) at final concentrations 
10, 50, 100 U/l.
siRNA transfection. MPS I, IIIA and IIIB cells were 
seeded in triplicate into 24-well tissue culture plates, 24 
h before transfection. Cells were transfected with Trans-
fection Reagent HiPerFect (Qiagen GmbH, Hilden, 
Germany) and 25 nM siRNAs (Applied Biosystems 
— Ambion, Austin, TX, USA) according to manufac-
turer’s instruction. Pre-designed siRNAs against human 
genes: XYLT1 (siRNA ID#112165, siRNA ID#29873), 
XYLT2 (siRNA ID#112168, siRNA ID#212974), GAL-
TI (B4GALT7) (siRNA ID#19329, siRNA ID#111770), 
GALTII (B3GALT6) (siRNA ID#112321, siRNA 
ID#112322) were the same as used and described previ-
ously by Dziedzic et al., (2010); while CS-GALNACT1 
(siRNA ID#s31518, siRNA ID#s31519), CS-GAL-
NACT2 (siRNA ID#s3880, siRNA ID#s3881) as pre-
sented in the work of Dziedzic and coworkers (2012). 
For further experimental procedures cell cultures were 
incubated for 24 or 48 h in standard culture conditions.
Cytotoxicity assay. The cytotoxicity assay (MTT as-
say) was conducted according to the method by Mos-
mann, (1983), with modifications. MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide)( Sigma, St 
Louis, MO, USA) dissolved at 1 mg/ml in RPMI 1640 
medium (Sigma, St Louis, MO, USA) was substituted for 
culture medium. After 2 hours of incubation at 37°C in 
humidified atmosphere of 5% CO2, MTT solution was 
removed from culture plates and replaced with DMSO 
(dimethyl sulfoxide, Sigma, St Louis, MO, USA). Plates 
were incubated for 5 minutes at room temperature to 
dissolve formazan products. Absorbance was measured 
at 550 nm using Victor Multilabel Plate Reader (Perki-
nElmer Inc. - Life Technologies, Walham, MA, USA). 
Estimation of siRNA cytotoxic effect was conducted 
24 h and 48 h after transfection procedure as described 
above while determination of laronidase cytotoxicity was 
carried out 24 h and 48 h after laronidase treatment.
Measurement of total GAGs level in cells. Fibro-
blasts from MPS I patients were seeded on 6-well tis-
sue culture plates and grown for 24 h at 37°C in a hu-
midified atmosphere of 5% CO2. Cells were transfected 
with siRNA oligonucleotide ID#19329 (GALTI) and/or 
treated with laronidase (100 U/l). After 48 h, cells were 
washed with PBS and harvested using 0.25% trypsin-eth-
ylene diaminetetraacetic acid solution (Sigma, St Louis, 
MO, USA). The pellet was digested with 0.03% papain 
solution from papaya latex (Sigma, St Louis, MO, USA) 
in 0.1 M sodium acetate buffer for 3 h at 65°C. After-
wards, a quantitative dye binding method — Blyscan 
(Biocolor Ltd, UK) was performed using 1,9-dimethyl-
methylene blue to measure sulfated GAGs. The amount 
of total glycosaminoglycans was standardized against 
DNA content measured spectrophotometrically using Pi-
coGreen dsDNA Quantification Kit (Molecular Probes - 
Invitrogen, Carlsbad, CA, USA).
Table 1. Characteristics of genotypes of MPS patients
MPS type MPS subtype Patient ID Mutations Mutations description
MPS I Hurler 20 Q70X/W402X STOP codon/STOP codon
Hurler 21 Q70X/Q70X STOP codon/STOP codon
Not determined 25 delD349/delD349 deletion/deletion
Not determined 54 Q70X/IVS7+2T>C STOP codon/substitution T→C
MPS III A 26 R74C/G90R Non-conservative aa substitution; destabilization of active site/ 
Non-conservative aa substitution
38 R74C/R74C Non-conservative aa substitution; destabilization of active site
B 27 Not determined –
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RESulTS
siRNAs and laronidase are not cytotoxic to MPS I and 
MPS III fibroblasts
Although both siRNA treatment and ERT had been 
tested previously for various therapeutical and biochemi-
cal parameters (see Dziedzic et al., 2010; 2012; Kakkis et 
al., 2001), they were not tested on in different cell lines 
of MPS patients. On the other hand, such testing may 
be important in the light of the high variability of MPS 
(Neufeld & Muenzer, 2001) and possible different reac-
tions of different cell lines, as well as different patients. 
Therefore, we tested the cytotoxicity of siRNA treatment 
on several cell lines derived from MPS I, MPS IIIA and 
MPS IIIB patients, and of the treatment with human re-
combinant α-l-iduronidase (laronidase, Aldurazyme®), an 
enzyme that is used in ERT for MPS I.
For testing the cytotoxicity of siRNAs, we used pre-
viously described oligonucleotides (Dziedzic et al., 2010; 
2012) and treated three MPS I and three MPS III cell 
lines of human fibroblasts. The experiments were per-
formed for 24 h and 48 h for each cell line. No cyto-
toxicity was observed for any tested MPS I cell lines and 
for any tested siRNAs (Fig. 1). Similar results were ob-
tained in experiments with two MPS IIIA and one MPS 
IIIB cell lines, however, one evident case of cytotoxic-
ity was found in one of the MPS IIIA cell lines (Fig. 2, 
panel III-B). Moreover, several cases of weak cytotoxic 
effects were also observed in the same cell line. All these 
cytotoxic effects occurred after 48 h (Fig. 2). These re-
sults indicate that siRNA treatment is generally not cyto-
Figure 1. siRNA has no cytotoxic effect on MPS I cell lines. 
Three lines of fibroblast from MPS I patients (cell line 20 – I; 21 – II; 25 – III) were transfected with the respective siRNAs: XYLT1 (siRNA 
ID#112165, siRNA ID#29873), XYLT2 (siRNA ID#112168, siRNA ID#212974), GALTI (B4GALT7) (siRNA ID#19329, siRNA ID#111770), GALTII 
(B3GALT6) (siRNA ID#112321, siRNA ID#112322), CS-GALNACT1 (siRNA ID#s31518, siRNA ID#s31519), CS-GALNACT2 (siRNA ID#s3880, siRNA 
ID#s3881). Panel A shows cytotoxicity effect after 24 h from transfection, and panel B after 48 h. For all graphs, values are presented as 
means of three biological replications with corresponding SD. ‘Ctrl’ represents untreated cells, ‘Mock ctrl’ indicates conditions when only 
the transfection reagent was used, ‘Positive ctrl’ indicates transfection with siRNA against the GAPDH gene, ‘Negative ctrl’ represents re-
sults with AllStars Negative Control siRNA.
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toxic for MPS cells, however, sporadic effects may occur 
in cells of particular patients.
Unlike for the siRNA treatment, no cytotoxic effects 
occurred in any of the MPS I cell lines treated with laro-
nidase (Fig. 3). These results confirm that ERT for MPS 
I is a generally safe treatment in as regards its cytotoxic-
ity.
Effects of ERT, siRNA and combined treatments on GAG 
storage in MPS I cells
We aimed to compare the effects of different treat-
ment methods on the reduction of GAG storage in var-
ious cell lines of MPS I. Three MPS I cell lines were 
treated with laronidase, siRNA or their combination for 
48 h. In control experiments, no significant effects of 
ERT, siRNA treatment or both methods used together 
on GAGs level was observed in wild-type human fibro-
blasts (results not shown).
As expected, ERT was more effective than siRNA 
treatment in reduction of GAGs storage in all tested cell 
lines (Fig. 4). However, different results were obtained 
for different cell lines when a combination of these two 
therapeutic approaches was employed. Depending on the 
cell line the decrease in GAG storage in cells treated si-
multaneously with both methods was less pronounced 
than that obtained with either method used alone (Fig. 
4A), similar to that observed in ERT (Fig. 4B), or more 
pronounced than that obtained with either method alone 
(Fig. 4C). Therefore, it appears that effects of various 
Figure 2. Cytotoxic effects of siRNAs to MPS IIIA and B cell lines. 
Three lines of fibroblast from MPS III patients (cell line 27 – I; 38 – II; 26 – III) were transfected with the respective siRNAs: XYLT1 (siRNA 
ID#112165, siRNA ID#29873), XYLT2 (siRNA ID#112168, siRNA ID#212974), GALTI (B4GALT7) (siRNA ID#19329, siRNA ID#111770), GALTII 
(B3GALT6) (siRNA ID#112321, siRNA ID#112322), CS-GALNACT1 (siRNA ID#s31518, siRNA ID#s31519), CS-GALNACT2 (siRNA ID#s3880, siRNA 
ID#s3881). Panel A shows cytotoxicity effects after 24 h from transfection, panel B, effects after 48 h. For all graphs values are presented 
as the means of three biological repetition with corresponding SD. ‘Ctrl’ represents untreated cells, ‘Mock ctrl’ indicates conditions when 
only the transfection reagent was used, ‘Positive ctrl’ indicates transfection with siRNA against the GAPDH gene, ‘Negative ctrl’ represents 
results with AllStars Negative Control siRNA.
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therapeutic methods may strongly depend on 
the cell line studied.
dISCuSSIoN
Although various therapeutic methods 
for MPS are currently being considered and 
tested, none of the available treatments is 
sufficiently effective to cure those severe dis-
eases (Jakóbkiewicz-Banecka et al., 2007; Beck, 
2010). Therefore, there is a need for the de-
velopment of new therapies or combinations 
of already known.
In this report we tested two treatment pro-
cedures for MPS, ERT and substrate depriva-
tion therapy based on the use of siRNA. In 
our approach we used several different cell 
lines derived from patients suffering from 
MPS I or MPS III. Perhaps surprisingly, we 
found that neither laronidase (Aldurazyme®) 
is cytotoxic for any of the MPS I cell lines 
tested, nor siRNAs are cytotoxic for most 
of the MPS I and MPS III cell lines tested. 
However some cytotoxicity of several siRNAs 
was observed for one MPS IIIA cell line. As 
this effect was also observed for the Mock 
control, the cell line sensitivity to the transfec-
tion agent rather than siRNA-dependent cyto-
toxicity should be considered in this case. We 
assume this could be an important discovery, 
as it might indicate that a generally safe thera-
peutic procedure for MPS can cause adverse 
effects in some patients. The siRNA-sensitive 
cell line derived from a patient suffering from 
MPS IIIA (Table 1, patient no. 26). This pa-
tient is a complex heterozygote, but one could 
not predict the unusual reaction to siRNA on 
the basis of such a genotype. Thus, we as-
Figure 3.  laronidase has no cytotoxic effect on MPS I cell lines. 
Four cell lines from MPS I patients (cell lines: 20, 21, 25, 54) were treated with 
appropriate concentrations of laronidase (IDUA) (10, 50, 100 U/l), and after 24 
h (A) or 48 h (B), cytotoxicity was assessed using the MTT assay.
Figure 4.  Effects of combined siRNA and laronidase treatment on MPS I cell lines.
Measurement of total GAGs was performed on three MPS I cell lines 48 h after siRNA transfection or/and laronidase (IDUA) treatment, 
according to procedures described in Methods. The results are presented as the percentage of untreated control ± S.D. Panel A shows 
results of experiments with cell line 54, panel B, cell line 21; and panel C, cell line 20.
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sume that the genetic background of this patient may be 
responsible for the siRNA sensitivity.
One of the therapeutic approaches that could poten-
tially result in efficacy higher than that achieved in tri-
als performed to date is combination of various treat-
ment procedures. Therefore, we tested the effects of 
a combination of ERT and treatment with siRNA on 
GAG storage in three different MPS I cell lines. Surpris-
ingly, the results varied significantly between these cell 
lines. The combined therapy was either less effective, 
of similar efficiency or more effective than ERT used 
alone, depending on the cell line (Fig. 4). Surprisingly, 
the highest efficacy was observed in the cell line of the 
genotype Q70X/W402X, i.e. bearing two nonsense mu-
tation in the IDUA gene (Fig. 4C). One might predict 
that the substrate deprivation therapy with the use of 
siRNA should be of the highest efficiency in cells con-
taining some residual activity of the deficient enzyme, 
and of the lowest efficiency in the case of cells unable to 
produce full-length enzyme. This is clearly not the case. 
Furthermore, the second cell line characterized by two 
null mutations responded differentially to the combined 
therapy (Fig. 4B), and the only cells potentially produc-
ing an a-L-iduronidase variant with some residual activ-
ity revealed the weakest efficiency in reduction of GAG 
levels when treated simultaneously with ERT and siRNA 
(Fig. 4A).
In summary, the results presented in this report indi-
cate that laronidase (Aldurazyme®) and siRNAs do not 
cause cytotoxicity in most MPS cell lines, however, some 
cytotoxic effects could occur in particular cell lines. 
Moreover, the efficacy of a combination of ERT and the 
use of siRNA depends on specific features of each cell 
line, thus, the combined therapy might potentially result 
in various effects in different patients.
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